Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Recursion Pharmaceuticals (RXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

An announcement from Recursion Pharmaceuticals ( ($RXRX) ) is now available. On October 29, 2025, Recursion Pharmaceuticals announced that Roche ...

Experts at SCOPE Europe 2025 confronted the challenges posed by rapid trial proliferation, digital transformation and ...

If you're an artist doing retro-style work (or you dream of getting started) and you'd like to do more with your Linux ...

Within the peer analysis summary, vital metrics for Agios Pharmaceuticals, Recursion Pharmaceuticals and Apellis ...

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Social media users took the "Scream" trailer to task in the wake of Barrera's removal following pro-Palestinian posts ...

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

As AGI approaches, experts say the future of work isn’t about replacement but collaboration where humans and AI together to ...

In a recent survey of law school admissions officers, 94% said the current political climate in the US played at least a ...